ZYBERNO
Stock Report
Updated Sep 1, 2026

FibroBiologics, Inc. (FBLG)

Healthcare • NASDAQ

$1.94

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
10.0/100
POOR BUSINESS
FibroBiologics, Inc. (FBLG) scores 10/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-536.8%)
Debt-to-Equity (Solvency Risk):GOOD (0.58x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-312.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

FibroBiologics, Inc. (FBLG) stock report — Zyberno Score 10/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, FBLG generated -$15.55M in Owner Earnings. Capital was deployed as follows: $219.00K invested in capital expenditures. Reinvestment rate: -0.1%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.94
Market Cap:$12.17M

Valuation Multiples (2)

P/B Ratio:2.62x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$11.55M

Price Action & Momentum (1)

% of 52-Week High:15.2%
B. Profitability Assessment

Return Metrics (5)

ROA:-225.1%
Reinvestment Rate:-0.1%
Fundamental Growth Rate (g):0.5%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$202.83
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.64x
Quick Ratio:2.64x
Cash Ratio:1.59x

Leverage Analysis (3)

Debt To Equity Ttm:0.58x
Debt-to-Equity Ratio:0.58x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-80.82x
Times Interest Earned:-80.82

Capital Structure (4)

Working Capital:3,637,000.00
Cash And Cash Equivalents:3,515,000.00
Long Term Debt:$1.08M
Net Debt:-$614.00K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$16.73M

Bottom Line Performance (3)

-$18.14M
Income Before Tax:$0.00
Ebitda Ttm:-16,466,000.00

Operating Expenses (5)

Operating Expenses:16,729,000.00
R And D Expense:8,197,000.00
Sga Expense:8,532,000.00
Income Tax Expense:$0.00
Interest Expense:206,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$7.93M
Current Assets:$5.85M
Ppe Net:710,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:3,293,000.00
Current Liabilities:2,213,000.00
Long Term Debt:$1.08M
Short Term Debt:$1.82M

Equity & Capital (3)

Equity:$4.64M
Retained Earnings:-$63.28M
Common Stock:300,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:1,821,000.00

Special Items (2)

Contract Liabilities:241,000.00
Stock Based Compensation:707,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$15.48M-$15.70M

Investment Activities (2)

Investing Cash Flow:$0.00
Capital Expenditures Ttm:219,000.00

Financing Activities (3)

Financing Cash Flow:$952.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:706,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:263,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-2.15
-$2.15
Earnings Per Share Ttm:-$2.89

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$2.61

Book Value & Capital (2)

Book Value Per Share:$0.74
Cash Per Share:0.56

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$15.55M

Damodaran Growth Analysis (2)

Reinvestment Rate:-0.1%
Fundamental Growth Rate (g):0.5%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):23.5%
C. Company Profile & Context

Corporate Information (6)

Symbol:FBLG
Company Name:FibroBiologics, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:6.27M
Shares Outstanding Basic:6.27M
Shares Outstanding Diluted:6.27M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 18:59:33 UTC
Data Timestamp:2026-08-22T05:29:44.562961
Scroll to Top